EA201170018A1 - Разагилин для изменения течения болезни паркинсона - Google Patents

Разагилин для изменения течения болезни паркинсона

Info

Publication number
EA201170018A1
EA201170018A1 EA201170018A EA201170018A EA201170018A1 EA 201170018 A1 EA201170018 A1 EA 201170018A1 EA 201170018 A EA201170018 A EA 201170018A EA 201170018 A EA201170018 A EA 201170018A EA 201170018 A1 EA201170018 A1 EA 201170018A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
parkinson
razagilin
change
flow
Prior art date
Application number
EA201170018A
Other languages
English (en)
Inventor
Рут Леви
Эли Эял
Тамар Горен
Шейла Орен
Наим Сайаг
Йонатан Вайсс
Мири Бен-Ами
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA201170018A1 publication Critical patent/EA201170018A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Способ изменения течения болезни Паркинсона путем периодического введения пациенту фармацевтической композиции, содержащей терапевтически эффективное количество разагилина или фармацевтически приемлемой соли разагилина, таким образом изменяя течение этого заболевания. Этот способ предусматривает снижение скорости прогрессирования; отсрочку необходимости в симптоматической терапии болезни Паркинсона; уменьшение риска необходимости симптоматической терапии болезни Паркинсона у больного болезнью Паркинсона и уменьшение функционального ухудшения состояния.
EA201170018A 2008-06-13 2009-06-12 Разагилин для изменения течения болезни паркинсона EA201170018A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US18972408P 2008-08-22 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Publications (1)

Publication Number Publication Date
EA201170018A1 true EA201170018A1 (ru) 2011-08-30

Family

ID=41415378

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170018A EA201170018A1 (ru) 2008-06-13 2009-06-12 Разагилин для изменения течения болезни паркинсона

Country Status (13)

Country Link
US (2) US20090312436A1 (ru)
EP (2) EP2296462A4 (ru)
JP (3) JP2011522892A (ru)
CN (2) CN103893160A (ru)
AU (2) AU2009258151A1 (ru)
BR (1) BRPI0909894A2 (ru)
CA (1) CA2727022A1 (ru)
EA (1) EA201170018A1 (ru)
IL (1) IL209131A0 (ru)
MX (1) MX2010013766A (ru)
NZ (1) NZ589445A (ru)
WO (1) WO2009151625A1 (ru)
ZA (1) ZA201008484B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
WO2009154777A2 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (en) 2009-07-09 2015-02-27 Ratiopharm Gmbh RAZAGILIN SALTS AND THEIR PHARMACEUTICAL PREPARATIONS
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
EP2603212A4 (en) * 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
WO2012015946A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
SG189454A1 (en) * 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
US9346746B2 (en) 2011-10-10 2016-05-24 Teva Pharmaceutical Industries, Ltd. R(+)-N-formyl-propargyl-aminoindan
CA2851274A1 (en) * 2011-10-10 2013-04-18 Konstantin Ulanenko Rasagiline citramide
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
US20150275302A1 (en) * 2014-04-01 2015-10-01 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
EP3432931A1 (en) * 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
JP2020513018A (ja) * 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
JP7473565B2 (ja) * 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69732984T2 (de) * 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
AU2002319615A1 (en) * 2001-07-20 2003-03-03 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2002367425B2 (en) * 2001-12-28 2006-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for urinary disturbance
WO2004045515A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
KR20140103356A (ko) * 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
ZA200903903B (en) 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
WO2009154777A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2485722A1 (en) * 2009-10-09 2012-08-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.

Also Published As

Publication number Publication date
JP2011522892A (ja) 2011-08-04
WO2009151625A1 (en) 2009-12-17
AU2016259315A1 (en) 2016-12-01
MX2010013766A (es) 2011-03-15
US20090312436A1 (en) 2009-12-17
US20140243418A1 (en) 2014-08-28
EP2666356A1 (en) 2013-11-27
AU2009258151A1 (en) 2009-12-17
ZA201008484B (en) 2012-05-30
CN103893160A (zh) 2014-07-02
JP2017081938A (ja) 2017-05-18
BRPI0909894A2 (pt) 2015-07-28
EP2296462A4 (en) 2011-06-15
IL209131A0 (en) 2011-01-31
EP2296462A1 (en) 2011-03-23
CA2727022A1 (en) 2009-12-17
NZ589445A (en) 2013-06-28
CN102065687A (zh) 2011-05-18
JP2015096532A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2010222367A5 (ru)
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
NZ714963A (en) Compositions and methods for treating anemia
EA201100305A1 (ru) Лечение респираторных заболеваний
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
JP2016512817A5 (ru)
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease